Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company built around complement inhibition, with pegcetacoplan as its core molecule. The company markets SYFOVRE for geographic atrophy secondary to age-related macular degeneration and EMPAVELI for paroxysmal nocturnal hemoglobinuria, with newer approvals expanding EMPAVELI into rare kidney diseases. Its business combines U.S. product commercialization with selective ex-U.S. partnering, most notably through Sobi for Aspaveli outside the United States. Apellis also continues to invest in pipeline programs that extend its complement biology platform into additional high-unmet-need diseases.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIntravitreal pegcetacoplan sold as SYFOVRE for geographic atrophy secondary to AMD.
Systemic pegcetacoplan sold as EMPAVELI for PNH and newly approved kidney indications.
Product supply and royalty revenue from the Sobi collaboration outside the U.S.
Preclinical and clinical programs extending complement inhibition into new diseases.
Products
Reported · share of revenue- Syfovre58.5 %
- Licensing and Other Revenue31.3 %
- Empaveli Pegcetacoplan10.2 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Apellis sells primarily to U.S. specialty physicians and the patients they treat, rather than to broad retail consumers. SYFOVRE is used by retina specialists treating geographic atrophy, while EMPAVELI is prescribed by hematologists and nephrologists for rare complement-mediated diseases such as PNH, C3G and IC-MPGN. The company also serves specialty pharmacies, specialty distributors, payors and reimbursement intermediaries that are central to access and uptake in these high-cost therapies. Outside the United States, Apellis monetizes its platform through Sobi, which buys product and pays royalties under the collaboration agreement.
They use SYFOVRE to slow progression in geographic atrophy, a chronic ophthalmology market with concentrated prescribers and reimbursement sensitivity.
They buy EMPAVELI through treating physicians to control complement-driven hemolysis in a rare disease setting.
They use EMPAVELI for newly approved kidney indications where specialist diagnosis and access pathways are critical.
They purchase and distribute product within the U.S. specialty channel and are important to inventory flow, returns and rebates.
Sobi buys product and commercializes Aspaveli outside the U.S., generating supply and royalty revenue for Apellis.
Strategy
Apellis is focused on maximizing the commercial opportunity for its two marketed pegcetacoplan products while broadening the label and geographic reach of the platform. Near term, the company is prioritizing U.S. commercialization of SYFOVRE and EMPAVELI, including market access, disease education, patient support and distribution execution. It is also pursuing additional approvals for EMPAVELI in rare kidney diseases and building the infrastructure needed to support future indications. Longer term, Apellis wants to extend complement inhibition into new programs, including partnered and internally developed pipeline assets, to reduce dependence on a small number of products.
SYFOVRE is the largest commercial opportunity and requires continued market education and reimbursement execution in a concentrated retina market.
New approvals in C3G and IC-MPGN broaden the addressable rare disease market and diversify revenue beyond PNH.
A broader pipeline reduces concentration risk and supports long-term growth if current products mature or face competition.
Geography
Apellis is operationally centered in the United States, where it recognizes product revenue from EMPAVELI and SYFOVRE sales and maintains its commercial infrastructure. The company retains U.S. commercialization rights for systemic pegcetacoplan and worldwide rights for intravitreal pegcetacoplan, but ex-U.S. monetization is partly handled through Sobi. Europe is strategically important because Aspaveli has European approval and generates collaboration revenue, including product supply and royalties. The business therefore has a U.S.-heavy revenue base with a smaller but meaningful international licensing footprint tied to regulatory approvals and partner execution.
Risks
Apellis remains exposed to the commercial risk of relying on a small number of products, especially SYFOVRE and EMPAVELI, so any slowdown in uptake, pricing pressure or competitive displacement would have an outsized effect. The company also faces execution risk in specialty commercialization because its products depend on concentrated prescribers, payor access, patient support and third-party distribution. Manufacturing and supply-chain dependence on a limited number of contract manufacturers creates operational vulnerability if a supplier is delayed, unavailable or underperforms. As a biotech company, Apellis also carries the usual clinical, regulatory and reimbursement risks, including the possibility that future indications or pipeline programs do not achieve approval or broad adoption.
- Dependence on a small number of productsImpact: HighLikelihood: Medium
Most revenue is tied to SYFOVRE and EMPAVELI, so any safety issue, slower uptake or label setback would materially affect results.
Exposure: SYFOVRE and EMPAVELI
- Competitive pressure in rare disease marketsImpact: HighLikelihood: Medium
EMPAVELI faces competition from oral and other therapies, which can reduce demand and pricing power.
Exposure: PNH and future EMPAVELI indications
- Third-party manufacturing and supply disruptionImpact: HighLikelihood: Medium
The company relies on a small number of contract manufacturers for active ingredient and finished product supply.
Exposure: Commercial and clinical supply
- Reimbursement and rebate pressureImpact: MediumLikelihood: Medium
Specialty drugs require payor access and can see higher rebates, returns and channel deductions that reduce net revenue.
Exposure: U.S. specialty pharmacy channel
- Pipeline and regulatory failureImpact: MediumLikelihood: Medium
Future growth depends on approvals and clinical success in new indications and programs, which are inherently uncertain.
Exposure: Development pipeline
Accounting
Judgemental itemsProduct sales are recorded net of estimated returns, rebates and other deductions, so reserve assumptions directly affect reported revenue.
Impact: Can shift revenue between periods if estimates change
Management estimates inventory in the distribution channel and expected sell-through to calculate returns and rebates.
Impact: Affects net sales and gross-to-net deductions
Revenue from product supplied and royalties is recognized based on partner activity and contract terms.
Impact: Creates timing variability in licensing and other revenue
Third-party manufacturing and ongoing development require judgment on inventory carrying values and accrued trial costs.
Impact: Can affect cost of sales, operating expenses and working capital
Similar listed companies
Publicly listed companies with a comparable business focus.
Alumis Inc
ALMS · Pharmaceutical Preparations
Amylyx Pharmaceuticals, Inc.
AMLX · Pharmaceutical Preparations
Exelixis, Inc
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Last updated: 24/09/2026